There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Sintx Technologies (SINT – Research Report) and Cyclo Therapeutics (CYTH – Research Report) with bullish sentiments. Sintx Technologies (SINT) In a report released yesterday, Tate Sullivan from Maxim Group maintained a Buy rating on Sintx Technologies, with a price target of $1.75. The company's shares closed last Monday at $0.62, close to its 52-week low of $0.40. According to TipRanks.
https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-sintx-technologies-sint-and-cyclo-therapeutics-cyth?utm_source=advfn.com&utm_medium=referral